Edition:
United Kingdom

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

38.23USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$38.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
379,094
52-wk High
$52.95
52-wk Low
$14.88

Chart for

About

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $812.47
Shares Outstanding(Mil.): 41.39
Dividend: --
Yield (%): --

Financials

  PTCT.OQ Industry Sector
P/E (TTM): -- 86.20 32.69
EPS (TTM): -3.10 -- --
ROI: -37.56 0.73 14.32
ROE: -64.70 1.82 16.04

BUZZ-PTC Therapeutics: Jumps on deal to buy Agilis Biotherapeutics

** Drug developer's shares up nearly 9 pct at $40.07 in early trading on Friday

20 Jul 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

18 Jun 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH, June 18 A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

18 Jun 2018

BRIEF-PTC Therapeutics Reports Q1 Loss Per Share $0.46

* PTC THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

09 May 2018

BRIEF-PTC Therapeutics announces presentation of preliminary data from Part 1,dose finding portion, of ongoing FIREFISH clinical trial

* PRELIMINARY CLINICAL DATA FROM FIREFISH TRIAL IN TYPE 1 SMA PATIENTS PRESENTED AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

25 Apr 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $43.12 --
Merck & Co., Inc. (MRK.N) $69.46 --
Bayer AG (BAYGn.DE) €77.81 -0.26
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates